Table 2. (a–c) The relationship between CYP2C8 and CYP2C9 genotypes in the breast cancer patient group.
| (a) | CYP2C8*1/*1 | CYP2C8*1/*4 | CYP2C8*4/*4 | n |
| CYP2C8*1/*1 | 445 | 76 | 3 | 524 |
| CYP2C8*1/*3 | 116 | 5 | 0 | 121 |
| CYP2C8*3/*3 | 7 | 0 | 0 | 7 |
| n | 568 | 81 | 3 | 652 |
| (b) | CYP2C9*1/*1 | CYP2C9*1/*3 | CYP2C9*3/*3 | n |
| CYP2C9*1/*1 | 438 | 67 | 2 | 507 |
| CYP2C9*1/*2 | 124 | 11 | 0 | 135 |
| CYP2C9*2/*2 | 8 | 0 | 0 | 8 |
| n | 570 | 78 | 2 | 650 |
| (c) | CYP2C9*1/*1 | CYP2C9*1/*2 | CYP2C9*2/*2 | n |
| CYP2C8*1/*1 | 498 | 25 | 1 | 524 |
| CYP2C8*1/*3 | 9 | 110 | 1 | 120 |
| CYP2C8*3/*3 | 0 | 1 | 6 | 7 |
| n | 507 | 136 | 8 | 652 |
Abbreviation: CYP=cytochrome P450.
Table 2a shows linkage disequilibrium (LD) between the CYP2C8*3 and CYP2C8*4 genotypes among the 652 breast cancer patients included. Table 2b shows LD between the CYP2C9*2 and CYP2C9*3 genotypes. Table 2c confirms the previously reported imperfect LD between CYP2C8*3 and CYP2C9*2. Genotype data on CYP2C9*2 were missing for one woman and CYP2C9*3 genotype data were missing for another woman.